Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils

Behavioural Pharmacology

Volumn 20, Issue 7, 2009, Pages 584-595

  Heldt, Scott A ^a,c   Davis, Michael ^a   Ratti, Emiliangelo ^b   Corsi, Mauro ^b   Trist, David ^b   Ressler, Kerry J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GSK   (Italy)

^c EMORY UNIVERSITY   (United States)

Author keywords

Anxiety; Context conditioning; Gerbil; Plus maze; Substance P

Indexed keywords

VOFOPITANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEAR; FOOTSHOCK; GERBIL; MALE; MAZE TEST; NONHUMAN; STARTLE REFLEX; TRAINING; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; GERBILLINAE; MALE; MAZE LEARNING; MODELS, ANIMAL; PIPERIDINES; RECEPTORS, NEUROKININ-1; STARTLE REACTION; TETRAZOLES;

EID: 70349665545     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32832ec594     Document Type: Article

References (99)

1. Aguiar MS, Brandao ML (1994). Conditioned place aversion produced by microinjections of substance P into the periaqueductal gray of rats. Behav Pharmacol 5:369-373.
2. Aguiar MS, Brandao ML (1996). Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test. Physiol Behav 60:1183-1186.
3. Ameli R, Ip C, Grillon C (2001). Contextual fear-potentiated startle conditioning in humans: replication and extension. Psychophysiology 38:383-390.
4. Ballard TM, Sanger S, Higgins GA (2001). Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. Eur J Pharmacol 412:255-264.
5. Bannon MJ, Deutch AY, Tam SY, Zamir N, Eskay RL, Lee JM, et al. (1986). Mild footshock stress dissociates substance P from substance K and dynorphin from Met- and Leu-enkephalin. Brain Res 381:393-396.
6. Barbaresi P (1998). Immunocytochemical localization of substance P receptor in rat periaqueductal gray matter: A light and electron microscopic study. J Comp Neurol 398:473-490.
7. Bassi GS, Nobre MJ, Carvalho MC, Brandao ML (2007). Substance P injected into the dorsal periaqueductal gray causes anxiogenic effects similar to the long-term isolation as assessed by ultrasound vocalizations measurements. Behav Brain Res 182:301-307.
8. Beresford IJ, Birch PJ, Hagan RM, Ireland SJ (1991). Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96 345. Br J Pharmacol 104:292-293.
9. Brodin E, Rosen A, Schott E, Brodin K (1994). Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions. Neuropeptides 26:253-260.
10. Caberlotto L, Hurd YL, Murdock P, Wahlin JP, Melotto S, Corsi M, Carletti R (2003). Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur J Neurosci 17:1736-1746.
11. Campeau S, Davis M (1995). Involvement of the central nucleus and basolateral complex of the amygdala in fear conditioning measured with fear-potentiated startle in rats trained concurrently with auditory and visual conditioned stimuli. J Neurosci 15:2301-2312.
12. Cheeta S, Tucci S, Sandhu J,Williams AR, Rupniak NM, File SE (2001). Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res 915:170-175.
13. Commons KG, Valentino RJ (2002). Cellular basis for the effects of substance P in the periaqueductal gray and dorsal raphe nucleus. J Comp Neurol 447:82-97.
14. Cruz AP, Frei F, Graeff FG (1994). Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 49:171-176.
15. Dableh LJ, Yashpal K, Rochford J, Henry JL (2005). Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 507:99-105.
16. Davis M (1979). Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology (Berl) 62:1-7. (Pubitemid 10226227)
17. Davis M (1992). Analysis of aversive memories using the fear-potentiated startle paradigm. In: Squire LR, Butters N, editors. Neuropsychology of memory. New York: The Guilford Press. pp. 35-41.
18. Dawson GR, Crawford SP, Collinson N, Iversen SD, Tricklebank MD (1995). Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology (Berl) 118:316-323.
19. De Araujo JE, Huston JP, Brandao ML (2001). Opposite effects of substance P fragments C (anxiogenic) and N (anxiolytic) injected into dorsal periaqueductal gray. Eur J Pharmacol 432:43-51.
20. Derrien M, McCort-Tranchepain I, Ducos B, Roques BP, Durieux C (1994). Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol Biochem Behav 49:133-141.
21. Duarte FS, Testolin R, De Lima TC (2004). Further evidence on the anxiogeniclike effect of substance P evaluated in the elevated plus-maze in rats. Behav Brain Res 154:501-510.
22. Duffy RA, Varty GB, Morgan CA, Lachowicz JE (2002). Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists. J Pharmacol Exp Ther 301:536-542.
23. Ebner K, Singewald N (2005). Effects of NK1 receptor antagonist administration on basal and stress-induced substance P release in the amygdala. J Neurochem 94:183.
24. Ebner K, Singewald N (2006). The role of substance P in stress and anxiety responses. Amino Acids 31:251-272.
25. Ebner K, Rupniak NM, Saria A, Singewald N (2004). Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci U S A 101:4280-4285.
26. Elliott PJ (1988). Place aversion induced by the substance P analogue, dimethyl-C7, is not state dependent: implication of substance P in aversion. Exp Brain Res 73:354-356.
27. Falls WA, Davis M (1995). Lesions of the central nucleus of the amygdala block conditioned excitation, but not conditioned inhibition of fear as measured with the fear-potentiated startle effect. Behav Neurosci 109:379-387.
28. File SE (1997). Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav 58:747-752.
29. File SE, Aranko K (1988). Sodium valproate and chlordiazepoxide in the elevated plus-maze test of anxiety in the rat. Neuropsychobiology 20:82-86.
30. Fong TM, Yu H, Strader CD (1992). The extracellular domain of substance P (NK1) receptor comprises part of the ligand binding site. Biophys J 62:59-60.
31. Fujimura Y, Yasuno F, Farris A, Liow J-S, Geraci M, Drevets W, et al. (2009). Decreased neurokinin-1 (substance p) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry [Epub ahead of print]. doi: 10.1016/j.biopsych.2008.12.027.
32. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, et al. (2005). Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58:132-142.
33. Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, et al. (1996). GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept 65:45-53.
34. Gentsch C, Cutler M, Vassout A, Veenstra S, Brugger F (2002). Anxiolytic effect of NKP608, a NK1-receptor antagonist, in the social investigation test in gerbils. Behav Brain Res 133:363-368.
35. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, et al. (2008). Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319:1536-1539.
36. Geracioti TD Jr, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS, et al. (2006). Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 163:637-643.
37. Gewirtz JC, McNish KA, Davis M (2000). Is the hippocampus necessary for contextual fear conditioning? Behav Brain Res 110:83-95.
38. Gitter BD, Waters DC, Bruns RF, Mason NR, Nixon JA, Howbert JJ (1991). Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol 197:237-238.
39. Griffante C, Carletti R, Andreetta F, Corsi M (2006). [3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain. Br J Pharmacol 148:39-45.
40. Grillon C, Davis M (1997). Fear-potentiated startle conditioning in humans: explicit and contextual cue conditioning following paired versus unpaired training. Psychophysiology 34:451-458.
41. Grillon C, Merikangas KR, Dierker L, Snidman N, Arriaga RI, Kagan J, et al. (1999). Startle potentiation by threat of aversive stimuli and darkness in adolescents: A multi-site study. Int J Psychophysiol 32:63-73.
42. Grillon C, Baas JMP, Pine DS, Lissek S, Lawley M, Ellis V, Levine J (2006). The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. Biol Psychiatry 60:760-766.
43. Guscott MR, Cook GP, Bristow LJ (2000). Contextual fear conditioning and baseline startle responses in the rat fear-potentiated startle test: A comparison of benzodiazepine/gamma-aminobutyric acid-A receptor agonists. Behav Pharmacol 11:495-504.
44. Hasenohrl RU, Gerhardt P, Huston JP (1990). Substance P enhancement of inhibitory avoidance learning: mediation by the N-terminal sequence. Peptides 11:163-167.
45. Heldt S, Sundin V, Willott JF, Falls WA (2000). Posttraining lesions of the amygdala interfere with fear-potentiated startle to both visual and auditory conditioned stimuli in C57BL/6J mice. Behav Neurosci 114:749-759.
46. Hietala J, Nyman MJ, Eskola O, Laakso A, Gronroos T, Oikonen V, et al. (2005). Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol 7:262-272.
47. Hogg S (1996). A review of the validity and variability of the Elevated Plus-Maze as an animal model of anxiety. Pharmacol Biochem Behav Anxiety Stress Depress 54:21-30.
48. Hokfelt T, Skirboll L, Everitt B, Meister B, Brownstein M, Jacobs T, et al. (1985). Distribution of cholecystokinin-like immunoreactivity in the nervous system. Co-existence with classical neurotransmitters and other neuropeptides. Ann N Y Acad Sci 448:255-274.
49. Joordens RJ, Hijzen TH, Peeters BW, Olivier B (1997). Control conditions in the fear-potentiated startle response paradigm. Neuroreport 8:1031-1034.
50. Joordens RJ, Hijzen TH, Olivier B (1998). The anxiolytic effect on the fear-potentiated startle is not due to a non-specific disruption. Life Sci 63:2227-2232.
51. Kapp BS, Pascoe JP, Bixler MA (1984). The amygdala: A neuroanatomical systems approach to its contribution to aversive conditioning. In: Butlers N, Squire LS, editors. The neuropsychology of memory. New York: The Guilford Press. pp. 473-488.
52. Kim JJ, Fanselow MS (1992). Modality specific retrograde amnesia of fear. Science 256:675-677.
53. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
54. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, et al. (2003). Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29:385-392.
55. Krase W, Koch M, Schnitzler HU (1994). Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats. Behav Brain Res 63:81-88. (Pubitemid 24238620)
56. LeDoux JE (1994). Emotion, memory and the brain. Sci Am 6:50-57.
57. Lee C, Rodgers RJ (1991). Effects of benzodiazepine receptor antagonist, flumazenil, on antinociceptive and behavioural responses to the elevated plus-maze in mice. Neuropharmacology 30:1263-1267.
58. Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92:180-185.
59. Maeno H, Kiyama H, Tohyama M (1993). Distribution of the substance P receptor (NK-1 receptor) in the central nervous system. Brain Res Mol Brain Res 18:43-58.
60. McLean S (2005). Do substance P and the NK1 receptor have a role in depression and anxiety? Curr Pharm Des 11:1529-1547.
61. McNish KA, Gewirtz JC, Davis M (1997). Evidence of contextual fear after lesions of the hippocampus: A disruption of freezing but not fear-potentiated startle. J Neurosci 17:9353-9360.
62. Michelga° rd A ° , Appel L, Pissiota A, Frans Ö, Langström B, Bergström M, Fredrikson M (2007). Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry 61:1002-1006.
63. Moser PC (1989). An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology (Berl) 99:48-53.
64. Nagano M, Saitow F, Haneda E, Konishi S, Hayashi M, Suzuki H (2006). Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey. Br J Pharmacol 147:316-323.
65. Patrick CJ, Berthot BD, Moore JD (1996). Diazepam blocks fear-potentiated startle in humans. J Abnorm Psychol 1:89-96.
66. Pelleymounter MA, Fisher Q, Schlesinger K, Hall M, Dearmey P, Stewart J (1986). The effect of substance P and its fragments on passive avoidance retention and brain monoamine activity. Behav Brain Res 21:119-127.
67. Pellow S, File SE (1986). Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat. Pharmacol Biochem Behav 24:525-529. (Pubitemid 16145187)
68. Pellow S, Chopin P, File SE, Briley M (1985). Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167.
69. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA (2004). Tachykinins and tachykinin receptors: A growing family. Life Sci 74:1445-1463.
70. Phillips RG, LeDoux JE (1992). Differential contributions of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106:274-285.
71. Quartara L, Altamura M (2006). Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets 7:975-992.
72. Quartara L, Maggi CA (1998). The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 32:1-49.
73. Randall JA (2001). Evolution and function of drumming as communication in mammals1. Am Zool 41:1143-1156.
74. Regoli D, Boudon A, Fauchere JL (1994). Receptors and antagonists for substance P and related peptides. Pharmacol Rev 46:551-599.
75. Riba J, Rodriguez-Fornells A, Urbano G, Morte A, Antonijoan R, Barbanoj MJ (2001). Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: A dose-response study. Psychopharmacology (Berl) 157:358-367.
76. Rigby M, O'Donnell R, Rupniak NM (2005). Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J Comp Neurol 490:335-353.
77. Risbrough VB, Brodkin JD, Geyer MA (2003). GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology 28:654-663.
78. Rodgers RJ, Dalvi A (1997). Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 21:801-810.
79. Rodgers RJ, Johnson NJ (1995). Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav 52:297-303.
80. Rodgers RJ, Lee C, Shepherd JK (1992). Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology (Berl) 106:102-110.
81. Rodgers RJ, Cao BJ, Dalvi A, Holmes A (1997). Animal models of anxiety: An ethological perspective. Braz J Med Biol Res 30:289-304.
82. Rosen A, Brodin K, Eneroth P, Brodin E (1992). Short-term restraint stress and S.C. saline injection alter the tissue levels of substance P and cholecystokinin in the peri-aqueductal grey and limbic regions of rat brain. Acta Physiol Scand 146:341-348.
83. Rupniak NM, Jackson A (1994). Non-specific inhibition of dopamine receptor agonist-induced behaviour by the tachykinin NK1 receptor antagonist CP-99,994 in guinea-pigs. Eur J Pharmacol 262:171-175.
84. Rupniak NM, Carlson EJ,Webb JK, Harrison T, Porsolt RD, Roux S, et al. (2001). Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12:497-508
85. Rupniak NM, Carlson EJ, Shepheard S, Bentley G, Williams AR, Hill A, et al. (2003a). Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608. Neuropharmacology 45:231-241.
86. Rupniak NM, Webb JK, Fisher A, Smith D, Boyce S (2003b). The substance P (NK1) receptor antagonist L-760735 inhibits fear conditioning in gerbils. Neuropharmacology 44:516-523.
87. Sananes CB, Davis M (1992). N-methyl-D-aspartate lesions of the lateral and basolateral nuclei of the amygdala block fear-potentiated startle and shock sensitization of startle. Behav Neurosci 106:72-80.
88. Saria A (1999). The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 375:51-60.
89. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V (2002). The tachykinin peptide family. Pharmacol Rev 54:285-322.
90. Siegel RA, Duker EM, Pahnke U, Wuttke W (1987). Stress-induced changes in cholecystokinin and substance P concentrations in discrete regions of the rat hypothalamus. Neuroendocrinology 46:75-81.
91. Smith DW, Hewson L, Fuller P,Williams AR,Wheeldon A, Rupniak NMJ (1999). The substance P antagonist L-760,735 inhibits stress-induced NK1 receptor internalisation in the basolateral amygdala. Brain Res 848:90-95.
92. Smith G, Harrison S, Bowers J,Wiseman J, Birch P (1994). Non-specific effects of the tachykinin NK1 receptor antagonist, CP-99,994, in antinociceptive tests in rat, mouse and gerbil. Eur J Pharmacol 271:481-487.
93. Szeidemann Z, Jakab RL, Shanabrough M, Leranth C (1995). Extrinsic and intrinsic substance P innervation of the rat lateral septal area calbindin cells. Neuroscience 69:1205-1221.
94. Teixeira RM, Santos AR, Ribeiro SJ, Calixto JB, Rae GA, De Lima TC (1996). Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311:7-14.
95. Varty GB, Cohen-Williams ME, Morgan CA, Pylak U, Duffy RA, Lachowicz JE, et al. (2002a). The gerbil elevated plus-maze II: Anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27:371-379.
96. Varty GB, Morgan CA, Cohen-Williams ME, Coffin VL, Carey GJ (2002b). The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation. Neuropsychopharmacology 27:357-370.
97. Winslow JT, Noble PL, Davis M (2007). Modulation of fear-potentiated startle and vocalizations in juvenile rhesus monkeys by morphine, diazepam, and buspirone. Biol Psychiatry 61:389-395.
98. Woolley ML, Haman M, Higgins GA, Ballard TM (2006). Investigating the effect of bilateral amygdala lesions on fear conditioning and social interaction in the male Mongolian gerbil. Brain Res 1078:151-158.
99. Young BJ, Helmstetter FJ, Rabchenuk SA, Leaton RN (1991). Effects of systemic and intra-amygdaloid diazepam on long-term habituation of acoustic startle in rats. Pharmacol Biochem Behav 39:903-909.